The hedgehog pathway, for which sonic hedgehog (Shh) is the most prominent ligand, is highly conserved and is tightly associated with embryonic development in a number of species. This pathway is also tightly associated with the development of several types of cancer, including basal cell carcinoma (BCC) and acute promyelocytic leukemia, among many others. Inactivating mutations in Patched-1 (PTCH1), leading to ligand-independent pathway activation, are frequent in several cancer types, but most prominent in BCC. This has led to the development of several compounds targeting this pathway as a cancer therapeutic. These compounds target the inducers of this pathway in Smoothened (SMO) and the GLI transcription factors, although targeting SMO has had the most success. Despite the many attempts at targeting this pathway, only three US FDA-approved drugs for cancers affect the Shh pathway. Two of these compounds, vismodegib and sonidegib, target SMO to suppress signaling from either PTCH1 or SMO mutations that lead to upregulation of the pathway. The other approved compound is arsenic trioxide, which can suppress this pathway at the level of the GLI proteins, although current evidence suggests it also has other targets. This review focuses on the safety and tolerability of these clinically approved drugs targeting the Shh pathway, along with a discussion on other Shh pathway inhibitors being developed.
Introduction
The hedgehog pathway is a highly conserved signaling pathway that is linked to many biological processes. This signaling pathway has been linked to development in many species, including humans [1] , and has also been linked to growth and patterning in many of these multicellular species, including the development of the neural system and bone development [2, 3] . The hedgehog pathway and its components have also been linked to several diseases, prominently including human cancer [4] . Because of the importance of this pathway to human cancer, there have been several attempts to target this pathway for cancer therapies, with few successes and many failures. In this review, we aim to provide an update on the successful agents targeting the hedgehog pathway that have been US FDA-approved for treatment in human cancers. We will also briefly discuss agents that are currently being developed to target this pathway for the treatment of cancer.
The Hedgehog Pathway in Cancer
Mammalian hedgehog signaling can be initiated by three unique ligands in sonic hedgehog (Shh), Indian hedgehog, and Desert hedgehog. However, Shh is the most widely expressed and also the most potent of these ligands [1, 5] . The ligand Shh is expressed as an inactive full-length protein that is proteolytically cleaved to two proteins; the N-terminal 19 kDa fragment is the active Shh ligand [6] . The receptor for this active Shh ligand is Patched-1 (PTCH1), a 12-transmembrane protein that binds the Shh ligand. Binding of Shh to PTCH1 relieves repression of Smoothened (SMO) by PTCH1, thereby activating SMO signaling activity (Fig. 1) . The activation of SMO ultimately decreases the interaction between suppressor of fused homolog (SUFU) and GLI proteins, which allows GLI proteins to enter the nucleus and bind transcriptional targets to regulate cellular gene expression. There are three GLI isoforms in mammals, i.e. GLI1-3, wherein gene expression can be induced by GLI1 and repressed by GLI3, whereas GLI2 can regulate expression in either direction. The GLI proteins are the terminal effectors of the Shh signaling pathway and regulate genes that control organismal patterning and development. Many of the genes regulated by GLI proteins are co-opted by cancer cells as they regulate several cancer-related processes, including proliferation, migration and invasion, as well as neovascularization [4] .
There have been numerous reports of genetic alterations in key components of the Shh pathway in different tumor types, which leads to constitutive signaling of this pathway. Furthermore, paracrine signaling of Shh may be an important factor in multiple tumor types [7, 8] . While there are reports of the Shh pathway being modified in several tumor types, such as breast, pancreatic, colorectal, and rhabdomyosarcoma, amongst others, genetic alterations in this pathway are most consistently seen in basal cell carcinomas (BCCs) and medulloblastomas [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The genetic alterations in this pathway are commonly loss-of-function changes to suppressors of the pathway (e.g. PTCH1, SUFU), or gainof-function changes to promotors of the pathway (e.g. SMO, GLI). This is very prevalent in BCC as PTCH1 has a gene inactivating alteration in 73% of these tumors, while SMO has a genetic activation in 20% [20] . Therapies targeted to the Shh pathway primarily inhibit the components that promote signaling flux through the pathway, including the Shh ligand itself, SMO, and GLI proteins. The most successful strategy has been to target SMO with small molecule compounds; the two FDA-approved drugs targeting this pathway use this strategy. Targeting SMO in BCC, for instance, has the potential to target the large percentage of these tumors that harbor inactivating alterations to PTCH1 or activating mutations to SMO. There are also inactivating alterations to SUFU in 8% of BCCs [20] and GLI1 is amplified in several tumor types [4] , but SMO inhibitors are unlikely to show efficacy against these populations. There have been attempts to develop inhibitors to Shh and GLI1 but these have yet to make it past clinical trials.
Currently Approved Sonic Hedgehog (Shh) Pathway Inhibitors
The first FDA-approved drug for cancer that targeted the Shh pathway was arsenic trioxide (ATO), which was approved in the year 2000 for the treatment of acute promyelocytic Fig. 1 The sonic hedgehog pathway. a In the absence of the Shh ligand, PTCH1 suppresses SMO, allowing for SUFU suppression of GLI1. b In the presence of the Shh ligand, PTCH1 repression of SMO is removed, allowing SMO to repress SUFU and leading to the release and nuclear translocation of GLI1. GLI1 and the other GLI proteins then promote a gene expression program that promotes multiple cancer phenotypes. The inhibitors to this pathway, the US FDAapproved inhibitors highlighted in green, have primarily targeted SMO, with some attempts to target Shh itself and the GLI proteins, but with little success. Shh sonic hedgehog, PTCH1 Patched-1, SMO Smoothened, SUFU suppressor of fused homolog, ATO arsenic trioxide leukemia (APL) [21] . While ATO has been proven to have significant effects suppressing the Shh pathway, it likely also targets other mechanisms promoting APL development and progression. Despite ATO being the first FDA-approved drug that has effects on the Shh pathway, the first FDAapproved agent that was specifically designed to target the Shh pathway was vismodegib (GDC-449), which was originally synthesized in 2009 and later approved in 2012 for the treatment of BCC [22, 23] . A year later in 2010, sonidegib (LDE225) was synthesized and was also later approved in 2015 for the treatment of BCC [24, 25] . These are currently the only approved agents targeting the Shh pathway with indications for cancer ( Table 1) .
Arsenic Trioxide (ATO)
Arsenic formulations have been used for their beneficial therapeutic effects as far back as the seventeenth century [21] ; however, chronic exposure to arsenic is also labeled as a carcinogen and has been shown to promote solid tumors [26, 27] . As an anticancer therapeutic, ATO has been shown to suppress growth in preclinical models in many tumor types, including breast cancer, pancreatic cancer, colon cancer, APL, melanomas, glioblastoma, and medulloblastoma, among others [28] [29] [30] [31] [32] . ATO was initially approved as a therapy for patients with APL who were refractory or had relapsed on retinoid and anthracycline chemotherapy [21] . This approval came after two landmark trials wherein APL patients had become resistant to standard chemotherapy or all-trans retinoic acid (ATRA) [33, 34] . ATO treatment increased the complete response rate from < 40% to > 90% and extended the time of this complete response [33, 34] . ATO has since been approved by the EU for patients with low-and intermediaterisk APL, and approved by the FDA in combination with ATRA for newly diagnosed, low-risk APL with the t(15;17) translocation of promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA). ATO has been investigated in several other tumor types, including those with increased Shh dependence, but APL is currently the only indication approved for ATO.
Mechanism of Action
APL develops in 95% of cases due to fusion of the PML gene on chromosome 15 with the RARA gene on chromosome 17, resulting in the PML-RARA t(15;17) fusion protein [35] . The PML-RARA fusion protein acts as a transcriptional repressor to block myeloid differentiation. Early studies indicated that ATO was effective against PML as exposure to ATO led to decreased levels of PML-RARA protein, as well as other cell survival proteins, and differentiation [29, [36] [37] [38] . These results led to studies that found significant clinical benefit for APL patients receiving ATO, and to eventual FDA approval [37, 39] . Despite this obvious link of ATO affecting the precise mechanism leading to APL, recent studies have also indicated that ATO has an effect in suppressing the Shh pathway. One of these early findings indicated that ATO suppressed GLI transcriptional activity that was not linked to cell viability, suggesting ATO was specifically targeting the Shh pathway [40] . Further confirmation was found when ATO suppressed GLI activity in the presence of SMO agonists or SMO-activating mutants [40] . These studies also indicated ATO suppressed GLI2 trafficking, and other studies with similar results indicated ATO directly bound to GLI1, suggesting ATO has inhibitory effects on several aspects of the Shh pathway [28, 40, 41] . These studies, as well as others showing similar suppression of the Shh pathway by ATO, have been shown in several tumor types [28, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Studies have also shown that ATO suppresses the Shh pathway in APL, including clinical studies that showed ATO treatment led to clinical response and significant suppression of the Shh pathway [50] . Thus, it appears that ATO has pleiotropic effects in the suppression III are 49 and 9 L/h, respectively. The metabolic breakdown of ATO, the pharmacodynamics, and the pharmacokinetics has led to approval for the treatment of ATO using a dose of approximately 0.15 mg/kg via intravenous administration with tretinoin, while the half-life of 10-14 h has led to daily administration according to these recommendations.
Serious and Life-Threatening Adverse Reactions
Perhaps the most serious life-threatening adverse reaction to ATO is QT interval disruption. For example, 38 of 99 patients treated with ATO for cancers developed prolonged QTc intervals [53] . Furthermore, several studies have also observed, although rare, development of torsade de pointes after treatment with ATO [54-56]. The ongoing management of these complications is accomplished by regular electrocardiogram (ECG) monitoring, discontinuation of other QT interval-prolonging drugs, and ensuring sufficiently high levels of serum magnesium and potassium [57] .
In addition to QT elongation, ATO can also cause differentiation syndrome, which can be fatal. When used in combination with tretinoin, ATO can lead to elevated levels of hepatic transaminase, which can be toxic to the liver. In addition, ATO is a carcinogen and teratogen, and is toxic to fetuses and embryos [27] .
Most Frequent Other Adverse Reactions
In addition to QT interval elongation and tachycardia, ATO has numerous adverse effects on the circulatory system, many of which involve levels of cells or substances in the blood, including leukocytosis, neutropenia, thrombocytopenia, hyperglycemia, hypokalemia, and hypomagnesemia. ATO also affects the gastrointestinal system and has caused vomiting, diarrhea, and abdominal pain. Reactions affecting the respiratory system include dyspnea, cough, and sore throat. Other general adverse reactions such as nausea, fever, rigor, fatigue, insomnia, edema, rash or itching, arthralgia, headaches, paresthesia, and dizziness can also occur ( Table 2) .
Various treatments are available to manage these adverse events. Leukocytosis, neutropenia, and thrombocytopenia can be managed with specific medications for these conditions, as well as transfusions; hyperglycemia can be managed with insulin injection and nutrition counseling; potassium and magnesium supplements have been used for hypokalemia and hypomagnesemia, respectively; and dyspnea can be treated using opioids with morphine, a common treatment for dyspnea in cancer patients [58].
Drug Interactions
Arsenic trioxide should not be taken with drugs that prolong the QT interval, alter electrolyte levels, or are hepatotoxic. The adverse reactions to ATO, especially QT prolongation, dictate avoiding these interactions for the safety of patients.
Postmarketing Spontaneous Reports of Adverse Reactions
Many additional adverse reactions to ATO have been reported postmarketing, including various cardiac disorders, nerve damage, seizure, confusion, deficiency of white and ATO Differentiation syndrome, elevated hepatic transaminase, QT interval elongation, tachycardia, leukocytosis, neutropenia, thrombocytopenia, hyperglycemia, hypokalemia, hypomagnesemia, vomiting, diarrhea, abdominal pain, dyspnea, cough, sore throat, nausea, fever, rigor, fatigue, insomnia, edema, rash, itching, arthralgia, headache, paresthesia, dizziness Vismodegib Vomiting, diarrhea, constipation, dysgeusia, muscle spasms, arthralgias, alopecia, weight loss, fatigue, nausea, decreased appetite Sonidegib Elevated creatine kinase, muscle spasms, musculoskeletal pain, myalgia, diarrhea, abdominal pain, vomiting dysgeusia, alopecia, pruritus, nausea, decreased weight, decreased appetite, headache, pain red blood cells and platelets, herpes zoster infection, muscle and bone pain, rhabdomyolysis, deafness, and toxic epidermal necrolysis. The development of other cancers, melanoma, pancreatic cancer, and squamous cell carcinomas have also been reported.
Vismodegib (GDC-0449)
Vismodegib was identified in 2009 from a compound screen with GLI-responsive luciferase cells, and was observed to have suppression of medulloblastoma allografts [23] . There was clear evidence that supported vismodegib inhibiting SMO, leading to tumor suppression in Shh-dependent preclinical models, including medulloblastoma, pancreatic cancer, colorectal cancer, lung cancer, prostate cancer, leukemia, and cholangiosarcoma, among others [23, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . Clinical trials have been undertaken in many of these tumor types, as well as other diseases with relevance to Shh signaling, but currently vismodegib has only been FDA-approved for BCC. Despite the potential efficacy in a myriad of tumor types, BCC was the obvious setting for the greatest clinical utility as it has constitutive activation of the Shh pathway in > 85% of cases [74] . This overwhelming majority of cases involving the Shh pathway is primarily due to mutations in PTCH1 that lead to ligand-independent activation of SMO [11, 20] . The first phase I clinical trial for vismodegib in BCC resulted in 18 of 33 patients having an objective response [75, 76] . The primary clinical evidence of efficacy for vismodegib in BCC was from a multicenter, two-cohort, nonrandomized clinical trial [22, 77] in which metastatic BCC patients showed a 33% objective response rate, whereas locally advanced BCC had an objective response rate of 43% [77] . Furthermore, stable disease was observed in 64% of metastatic BCC patients and 38% of locally advanced BCC patients [77] . These outcomes resulted in a median response duration of > 7 months and progression-free survival of > 9 months [77] . Additionally, there has been an overall survival increase from 24 to 33.4 months for BCC patients since vismodegib became available [78, 79] . To further this point, the historical median survival of BCC prior to 1990 was approximately 8 months, but is now approximately 7 years due to the introduction of agents targeting the Shh pathway, such as vismodegib and sonidegib [80] [81] [82] [83] . The summation of these encouraging clinical results led to the 2012 FDA approval of vismodegib for metastatic or locally advanced BCC.
Mechanism of Action
Vismodegib was synthesized as a cyclopamine derivative and identified to inhibit SMO via a GLI luciferase reporter cell line [23] . Further studies confirmed that vismodegib directly bound to SMO via competitive binding assays and molecular docking prediction studies [59, 63, 65, 69, 70, 72] . In confirming that vismodegib binds to SMO, it was also observed that vismodegib exposure could induce a mutation in SMO that ablated the interaction of the drug with SMO [72, 84] . This mutation was observed in patient samples and animal models that led to vismodegib adaptive resistance [72] .
Metabolic Profile
Vismodegib has a bioavailability of 31.8% upon oral administration [85] . At steady-state levels, which is achieved unusually fast in 7-14 days, more than 99% of the drug binds to proteins in the plasma, including alpha 1-acid glycoprotein (AAG) and human serum albumin, and is unaffected by concentration until 100 μM [85] . It is metabolized primarily by cytochrome P450 (CYP) enzymes, with CYP3A4, CYP3A5, and CYP2C9 producing most of the metabolites [86] . Vismodegib has an unusually long half-life of approximately 12 days after a single dose of 150 mg [87] ; however, its half-life with continuous administration on a daily basis is approximately 4 days [22] .
Serious and Life-Threatening Adverse Reactions
Vismodegib, similar to other drugs targeting the hedgehog pathway, is a teratogen. The hedgehog pathway is an important element in the development of various organs and organ systems [88] . A drug that disrupts this pathway is therefore expected to be, and is, detrimental to the development of embryos and fetuses. The FDA recommends verifying pregnancy status within 7 days of the start of treatment with vismodegib, and use of contraception during treatment and for 24 months after the end of treatment. It is worth noting that vismodegib not only targets the Shh pathway more specifically than ATO but also does not have the side effect of QT internal prolongation that comes with ATO [89] .
Most Frequent Other Adverse Reactions
Several of the most common adverse reactions involve the gastrointestinal system and include vomiting, diarrhea, constipation, and dysgeusia (disorder of taste). The drug also affects the musculoskeletal system and can cause muscle spasms and joint pain (arthralgias). Another common adverse reaction is alopecia, and other general adverse effects include weight loss, fatigue, nausea, and decreased appetite (Table 2 ) [75] .
These adverse events do have sufficient approaches to management. Strategies for managing dysgeusia, decreased appetite, and weight loss include nutritional consultation and changes in the preparation of foods [90, 91] . Furthermore, there are also medicinal options, ranging from fish oil supplementation to corticosteroids [92] . Attention to other factors that may affect taste, such as oral hygiene, infection, acid reflux, and postnasal drip, have also been reported to improve symptoms [93] . Proper hydration, stretching and other light physical activity may help in the prevention of muscle spasms and join paint. Calcium blockers, nerve pain medication, and sports drinks are also recommended. For muscle spasms higher than grade 3, stopping treatment for 2-4 weeks may help, as well as the addition of other medications such as gabapentin, among other options [90, 92] . For the management of alopecia, 2-5% minoxidil is the most commonly suggested treatment; strategies for concealing hair loss can also be considered [90, 92, 93] . Serotonin inhibitors taken before and during treatment can be used to prevent nausea [90] .
Drug Interactions
When administered with fluconazole, a moderate inhibitor of CYP2C9 and CYP3A4, vismodegib was found to have increased steady-state concentrations, while itraconazole, a strong inhibitor of CYP3A4, and rabeprazole, a proton pump inhibitor, were found to have no effect [94] . Vismodegib may inhibit CYP2C8, CYP2C9, CYP2C19, and BCRP transporter [86] . These drug interactions are important for the safety of vismodegib administration and minimizing the likelihood of the occurrence and severity of the adverse events described earlier in this review.
Postmarketing Spontaneous Reports of Adverse Reactions
Vismodegib has been associated with hepatotoxicity postmarketing. As of January 2013, 23% of adverse event reports on the FDA Adverse Events Reporting System have included liver toxicity [95] . An increase in blood phosphocreatine kinase (CK) was also reported postmarketing [96] .
Sonidegib (LDE-225)
Sonidegib (LDE-225) was identified in 2010 using a GLIresponsive luciferase reporter cell line, and had efficacy in a medulloblastoma allograft model [25] . This study, and others, confirmed sonidegib interacted with and inhibited SMO [25, 59, 63, 69, 70] . Sonidegib has shown efficacy in multiple tumor types in preclinical models, including medulloblastoma, ovarian cancer, glioblastoma, melanoma, renal cell carcinoma, leukemia, and breast cancer, among others [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] . As mentioned earlier, there has been a very large increase in median survival since these Shh pathway inhibitors were introduced, from approximately 8 months to approximately 7 years [80] [81] [82] [83] . Clinical trials have been undertaken for sonidegib in many of these tumors types, but BCC remains the only FDA-approved indication. Due to the prevalence for the Shh pathway to be activated in BCC, sonidegib was an obvious compound for the treatment of BCC. A very early treatment with sonidegib as a topical treatment suggested it may have efficacy in nevoid BCC [112] . In an initial phase I trial in patients with advanced solid tumors, 37.5% of BCC patients and 33% of medulloblastoma patients showed objective tumor responses [113] . This trial established sonidegib as safe, with possible efficacy, leading to further trials. A phase II, multicenter, randomized, double-blind trial was later completed in locally advanced or metastatic BCC, with patients receiving either a low (200 mg) or high (800 mg) dose of sonidegib [114] . The patients receiving the low dose showed a 36% objective response rate, with the high-dose group achieving a 43% objective response rate [114] . A later update after 12 months of follow-up with these patients indicated a sustained response as the low-dose group had a 57.6% objective response rate in locally advanced BCC, whereas the high-dose group maintained a 43.8% response rate in locally advanced BCC [115] . The results of this trial led to FDA approval in 2015 for adult patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Mechanism of Action
Sonidegib was identified via a screen in a GLI luciferase reporter cell line, and binding to SMO was confirmed via a GLI1 IC50 shift assay [25] . Molecular prediction docking studies further predict sonidegib binds to SMO in the 'drug binding pocket' [59, 63, 69, 70] . The same mutations in the drug binding pocket that led to vismodegib resistance were also observed to cause sonidegib resistance [116] , suggesting these drugs share a similar mechanism of action.
Metabolic Profile
Sonidegib has an absorption rate of < 10% upon oral administration. However, when taken with a meal high in fat, absorption increases 7.4-to 7.8-fold [117] . Sonidegib reaches steady-state levels after approximately 4 months. It has a very high volume of distribution of 9166 L, suggesting high accumulation in tissues [118] . More than 97% of the sonidegib in plasma remains bound to proteins and is unaffected by concentration. Sonidegib has an estimated half-life of 28 days, and is metabolized primarily by CYP3A enzymes in the liver [119] . These factors have led to a dosing schedule of 200 mg administered once daily via oral administration on an empty stomach.
Serious and Life-Threatening Adverse Reactions
As sonidegib is an inhibitor of the Shh pathway, like vismodegib, it is also toxic to fetuses and embryos and is a teratogen. Sonidegib has been shown to elevate CK levels in several patients and was often accompanied by musculoskeletal complications [113] . Thus, CK levels should be monitored before and periodically throughout the duration of treatment with this drug. Similar to vismodegib, sonidegib is more specific than ATO and does not result in QT interval prolongation [120] .
Most Frequent Other Adverse Reactions
Sonidegib affects the musculoskeletal system in various ways, with symptoms including muscle spasms, musculoskeletal pain, and myalgia. It can also cause gastrointestinal disturbances, including diarrhea, abdominal pain, vomiting, and dysgeusia. Sonidegib can lead to alopecia and pruritus (severe itching of skin). Other common adverse reactions are nausea, decreased weight, decreased appetite, headache and pain (Table 2 ) [113] . The management of these adverse reactions is similar to those listed for vismodegib. An additional factor worth mentioning is that pruritus can be treated with emollients, antipruritic creams, and antihistamines [93] .
Drug Interactions
Sonidegib users should avoid concurrently using any strong or moderate CYP3A inhibitors or inducers. Moderate inhibitors may be used if necessary but only for < 14 days and with close monitoring. Some strong CYP3A inhibitors include saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, and nefazodone, while moderate inhibitors include atazanavir, diltiazem, and fluconazole. Inducers of CYP3A include carbamazepine, efavirenz, modafinil, phenobarbital, phenytoin, rifabutin, rifampin and St. John's Wort. These drug interactions are of direct importance to the safety of this drug in patients, and minimizing as much as possible the likelihood and severity of the adverse reactions described earlier in this review.
Shh Pathway Agents Under Development
As described earlier, the primary drug targets for the Shh pathway are molecules that promote active signaling. The primary targets that have been attempted to be therapeutically targeted are Shh itself, SMO, and GLI proteins, with GLI1 being the primary target (Table 3 ).
Agents Targeting Shh
5E1 is a monoclonal antibody that binds the Shh ligand, preventing its interaction with PTCH1 [121, 122] . This antibody has been known to suppress the growth of esophageal patient-derived xenograft (PDX) models in combination with radiation [111] . 5E1 was also shown to enhance the effect of platinum-based chemotherapy delivered concurrently with radiation plus chemotherapy (RTCT) on cervical cancer xenografts, but there was no effect of 5E1 as a single agent [98] . 5E1 also enhanced the effect of platinum-based therapy in models of gastric cancer [123] . In a mouse model of breast cancer, 5E1 has been shown to decrease tumor size, as well as liver and pancreatic metastases [124] . Furthermore, in a mouse model of medulloblastoma, 5E1 was effective as monotherapy in suppressing tumor growth and extending survival time [125] . 5E1 also reduced primary tumor growth and metastasis in an orthotopic mouse pancreatic cancer model as a single agent [7] .
Robotnikinin is a 12-membered macrocycle compound that was discovered through screening for molecules that suppress the Shh pathway [126] . This compound was found to directly bind Shh and prevent its interaction with PTCH1, leading to suppression of GLI1 activity [126] . This compound has yet to show any antitumor effects in preclinical models.
During the synthesis of Shh, the enzyme SHHat catalyzes the final steps to attach a palmitate to the Shh protein [127, 128] . The RU-SKI 43 compound was found from screening for inhibitors of SHHat that suppressed Shh production and signaling [129] . This compound was observed to reduce proliferation and anchorage-independent growth of breast cancer cells [130] , as well as pancreatic tumor growth [131] .
Agents Targeting Smoothened
Cyclopamine is an alkaloid from Veratrum californicum that is one of the early synthesized compounds to have significant inhibitory action toward SMO and suppressing signaling through the Shh pathway [132, 133] . Cyclopamine was shown to have several antitumor effects in many tumor types [134] [135] [136] [137] ; however, this compound had many adverse effects, preventing its widespread clinical use and leading to the development of second-generation derivatives of cyclopamine, such as vismodegib described earlier.
Another derivative of cyclopamine is saridegib (IPI-926), which has shown antitumor activity in models of medulloblastoma, ovarian cancer, chondrosarcoma, and osteosarcoma [138] [139] [140] [141] [142] . Early-stage clinical trials of saridegib have been conducted that have shown favorable pharmacodynamics and pharmacokinetics, while having some antitumor activity toward solid tumors [143] [144] [145] [146] . However, saridegib was not recommended for further development in patients with myelofibrosis or pancreatic cancer [145, 147] . Clinical trials of saridegib for other tumor types, such as head and neck cancer (NCT01255800) and chondrosarcoma (NCT01310816), have been completed but not all results have been made public as at the time of this review. No new clinical trials for saridegib have been initiated.
Another cyclopamine derivative, BMS-833923 (XL139), has shown effectiveness in suppressing SMO [59, 148, 149] . Preclinical studies indicate efficacy of BMS-833923 in esophageal, prostate, cholangiosarcoma, and lung cancers [148] [149] [150] [151] . A number of early-phase clinical trials were initiated with BMS-833923 in the early part of this decade, but little success has led to Bristol-Myers Squibb discontinuing their research in the area of SMO inhibitors (see NCT01218477). Another compound, glasdegib (PF-04449913), described in 2011, has since made significant progress in preclinical and clinical settings [152] . Glasdegib was described to interact with and suppress SMO activity, which was effective in targeting myeloid leukemias in preclinical models [59, [152] [153] [154] [155] . Several phase I clinical trials of glasdegib have reported favorable drug profiles, with some instances of efficacy suggesting further development [156] [157] [158] [159] [160] [161] [162] [163] . A phase II trial with glasdegib plus cytarabine/daunorubicin was well tolerated and showed clinical activity in patients with untreated acute myeloid leukemia (AML) and highrisk myelodysplastic syndrome (MDS) [164] . A number of phase I and II trials of glasdegib are ongoing, in both hematological and solid tumors, as well as one phase III trial in AML (NCT03416179). These clinical successes have led to the FDA recently granting priority review for glasdegib in untreated AML.
The TAK-441 compound is another SMO inhibitor synthesized in the last decade with some clinical relevance [165] . It has a potent ability to inhibit SMO and the Shh pathway and has shown an ability to suppress the growth of multiple solid tumor types in preclinical studies [59, [165] [166] [167] [168] [169] . One unfortunate side effect of SMO inhibition can be adaptive mutations in the SMO gene, making them resistant to vismodegib or cyclopamine [170] . An encouraging finding is that in preclinical studies, TAK-441 has been shown to maintain activity in cells expressing these SMO adaptive mutants, suggesting it may be highly relevant to resistant patients [171, 172] . To date, there has only been one clinical trial of TAK-441, a phase I trial that found TAK-441 was well tolerated and showed preliminary antitumor activity in advanced solid tumors [173] . No further trials have been registered for TAK-441, therefore the current status and future plans for development are unknown.
Taladegib (LY2940680) is another inhibitor developed in recent years with potent SMO binding and inhibitory action, including inhibition of the adaptive SMO mutant [70, [174] [175] [176] . Two separate phase I trials indicated a favorable safety profile for taladegib in patients with solid tumors, including patients resistant to previous Shh therapies [177, 178] . Several phase I and II trials of taladegib in multiple solid tumor types are ongoing.
The LEQ506 compound has also been developed in recent years and has the ability to bind and inhibit SMO, leading to suppression of Shh pathway signaling [179, 180] . This binding to SMO included binding to the adaptive mutant SMO following vismodegib administration [179] . This compound was subjected to a phase I trial in patients with advanced solid tumors but the results have yet to be posted.
Lastly, itraconazole is a known antifungal drug, but has shown an ability to inhibit SMO in BCC [181] [182] [183] . Itraconazole has seen efficacy in combination with other chemotherapies in phase II trials for castration-resistance prostate cancer, non-small cell lung cancer, and BCC [184] [185] [186] . There are many ongoing trials that include itraconazole with the purpose of treating several different solid tumor types, although these are all phase I and II trials. In addition, there are higher-level phase trials that have included itraconazole, but these are all for its antifungal properties.
Agents Targeting GLI1
Genistein is an isoflavone isolated from Genista tinctoria that is widely available in legumes and plant foods. Genistein has been found to suppress GLI1 in recent years, leading to an ability to suppress several tumor types and, in particular, the cancer stem cell niche [187] [188] [189] [190] [191] . Exactly how genistein suppresses GLI1 remains to be understood, but many of its antitumor properties have been attributed to suppression of the Shh pathway despite genistein also suppressing several other important tumor-related molecules. Phase I trials of genistein have shown a very favorable safety profile, leading to several phase II trials wherein genistein showed some efficacy in prostate cancers but had mixed results in pancreatic cancers [192] [193] [194] [195] [196] [197] . Genistein is being evaluated in several ongoing trials, mostly in phase I or II, and, as is often the case with natural compounds, it is frequently being evaluated as a prevention agent.
GANT61 is a compound synthesized from a GLI luciferase drug screen that effectively reduced GLI1/2 DNA binding [198] . GANT61 has shown to have inhibition of GLI activity in multiple preclinical models that also leads to suppression of tumor growth and proliferation [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] . However, at the time of writing of this review, no clinical trials have been registered for this lone GLI-specific inhibitor.
Resistance to Shh Pathway-Targeted Therapies
Several agents that target the Shh pathway have been shown to develop resistance, including FDA-approved agents as described earlier [72, 116, 139] . This is highly related to drug safety as patients develop resistance to agents, and the dose escalation required to maintain tumor suppression can become toxic or cause patients to be entirely removed from such therapies. As mentioned earlier, resistance to vismodegib and sonidegib occurs due to an adaptive mutation in SMO causing ineffectiveness of these compounds to inhibit SMO activity [72, 116] . It seems two primary strategies have been used to attempt to cover the resistance of these FDA-approved therapies: (1) developing alternative inhibitors that can inhibit vismodegib-resistant SMO activity; or (2) combinatorial therapy with other drugs. Many of the therapies under development that have been described earlier in this review have been tested to ascertain whether they can sufficiently inhibit SMO in the presence of the adaptive mutation caused by long-term vismodegib or sonidegib treatment. Furthermore, the continued development of new inhibitors is due to the resistance these approved therapies eventually succumb to. Clinical trials have been occurring, or are continuing to occur, with combinatorial studies of vismodegib and other agents such as radiation (NCT02956889, NCT01835626), temozolomide (NCT01601184), gemcitabine (NCT01713218, NCT01195415, NCT01064622, NCT00878163, NCT01088815), paclitaxel (NCT02694224), bevacizumab (NCT00636610), oxaliplatin (NCT00982592), and decitabine (NCT02073838). Similarly, sonidegib is also currently in clinical trials in combination with other therapies such as everolimus (NCT02138929), docetaxel/paclitaxel (NCT02027376, NCT01954355, NCT02182622), gemcitabine (NCT01487785, NCT01431794, NCT02358161, NCT03434262), cisplatin (NCT01579929), and fluorouracil (NCT01485744). Many of these trials are ongoing and do not have the results available; however, the few with obtainable results seem to have mild, if any, enhancement of the efficacy. It is also unclear how these combinatorial studies will affect adverse events as the studies above with available information indicate more events in some cases, while others see mild effects. Completion of many of these studies, and any information on developing resistance, will certainly increase our understanding of how to overcome resistance to these therapies and the correct populations likely to benefit.
In addition to these resistance mechanisms in FDAapproved therapies, there is a small amount of evidence for resistance to agents currently under development. Saridegib, which targets SMO, was shown to inhibit medulloblastoma in a mouse model and increase the lifespan of these animals, however these animals did develop resistance [139] . Nonetheless, many of these agents have not been tested for long time periods of time to establish whether they will develop resistance. Aside from the study mentioned above regarding saridegib, there are very few preclinical long-term studies that would allow such an observation. Furthermore, while some of these agents have made it to clinical trials, none have currently made it past phase II trials, leading to insufficient evidence as to whether any of them will induce adaptive resistance in patients.
Conclusions
Evidence continues to be generated from many laboratories indicating the importance of the Shh pathway in tumor initiation and progression. In particular, this pathway seems highly important to brain tumors, especially medulloblastoma, and skin cancers, especially BCC. The primary target of this pathway that has shown any successful efficacy is SMO; however, targeting this molecule can lead to adaptive mutations that induce resistance. The development of next-generation SMO inhibitors should take into account this adaptive mechanism. Due to the lack of an enzymatic domain in the GLI transcription factors, these proteins are likely going to be difficult to directly target with future drug development. Despite this drawback, there continues to be attempts to therapeutically target transcription factors, and a breakthrough in this area could lead to new vigor in the attempt to target GLI proteins. Overall, the Shh pathway appears to be important for many types of tumors and at different stages of the disease. Therefore, it is in the interests of future patients to continue basic research on this pathway and continue drug development towards viable targets in the Shh pathway. 
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